David Feifel

Safety and tolerability of a rapidly escalating dose-loading regimen for risperidone.

Sensorimotor gating effects produced by repeated dopamine agonists in a paradigm favoring environmental conditioning.

Information processing deficits in acutely psychotic schizophrenia patients medicated and unmedicated at the time of admission.

A systemically administered neurotensin agonist blocks disruption of prepulse inhibition produced by a serotonin-2A agonist.

Altered extracellular dopamine concentration in the brains of cholecystokinin-A receptor deficient rats.

Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and a neurotensin agonist, but not haloperidol: a potential predictive model for novel antipsychotic effects.

Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam.

Prepulse inhibition in patients with non-psychotic major depressive disorder.

Inhibitory deficits in ocular motor behavior in adults with attention-deficit/hyperactivity disorder.

A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.

Rapid oral loading of extended release divalproex in patients with acute mania.

A systematic review of modafinil: Potential clinical uses and mechanisms of action.

Upregulation of striatal dopamine-2 receptors in Brattleboro rats with prepulse inhibition deficits.

The relationship between sensorimotor gating and clinical improvement in acutely ill schizophrenia patients.

The effects of cross-fostering on inherent sensorimotor gating deficits exhibited by Brattleboro rats.

The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats.

Dosing of divalproex extended release.

The reversal of amphetamine-induced locomotor activation by a selective neurotensin-1 receptor agonist does not exhibit tolerance.

The neurotensin-1 receptor agonist PD149163 blocks fear-potentiated startle.

Prepulse inhibition of startle in adults with ADHD.

Commentary: why diagnose and treat ADHD in adults?

Attention-deficit/hyperactivity disorder in adults: recognition and diagnosis of this often-overlooked condition.

Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study.

The acute and subchronic effects of a brain-penetrating, neurotensin-1 receptor agonist on feeding, body weight and temperature.

The use of placebo-controlled clinical trials for the approval of psychiatric drugs: part I-statistics and the case for the "greater good".

Transforming the psychiatric inpatient unit from short-term pseudo-asylum care to state-of-the-art treatment setting.

Use of risperidone long-acting injectable in a rural border community clinic in southern california.

Treatment of autistic children.

More depressing news on antidepressants: should we panic?

The Psychiatric Emergency Research Collaboration-01: methods and results.

The Use of Placebo-Controlled Clinical Trials for the Approval of Psychiatric Drugs: Part II-Ethical Considerations Related to the Individual Participant.

Effects of neurotensin-2 receptor deletion on sensorimotor gating and locomotor activity.

Daytrana: the first year.

ADHD in adults: the invisible rhinoceros.

An atomoxetine tutorial.

Potential complications of combining intramuscular olanzapine with benzodiazepines in emergency department patients.

Promise and pitfalls of animal models of schizophrenia.

Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients.

A retrospective analysis of intramuscular haloperidol and intramuscular olanzapine in the treatment of agitation in drug- and alcohol-using patients.

Strattera: ups, downs, and emerging uses.

Time to feel good: the therapeutic time course of antidepressants.

When common clinical practice meets evidence-based medicine.

Recent changes in prescriptions for antipsychotics in children and adolescents.

Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine.

Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial.

Is oxytocin a promising treatment for schizophrenia?

A Naturalistic, Single-blind Comparison of Rapid Dose Administration of Divalproex ER Versus Quetiapine in Patients with Acute Bipolar Mania.

Clozapine and PD149163 elevate prepulse inhibition in Brown Norway rats.

A comparison of the safety of olanzapine and haloperidol in combination with benzodiazepines in emergency department patients with acute agitation.

Efficacy and safety of the novel α(4)β (2) neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study.

The effects of oxytocin and its analog, carbetocin, on genetic deficits in sensorimotor gating.

Oxytocin as a potential therapeutic target for schizophrenia and other neuropsychiatric conditions.

Dramatic improvement in sexual function induced by intranasal oxytocin.

The psychopharmacology of agitation: consensus statement of the american association for emergency psychiatry project Beta psychopharmacology workgroup.

A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation.

A 9-week, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy and safety of modafinil as treatment for adults with ADHD.

Adjunctive intranasal oxytocin improves verbal memory in people with schizophrenia.

Oxytocin in schizophrenia: a review of evidence for its therapeutic effects.

The effect of intranasal oxytocin treatment on conditioned fear extinction and recall in a healthy human sample.

Oxytocin and psychotherapy: a pilot study of its physiological, behavioral and subjective effects in males with depression.

In reply:.

Limited evidence that benzodiazepines are beneficial in the treatment of disturbed behaviour.

Not disappointed by anxiety: a reply to Cardoso and Ellenbogen's commentary "Oxytocin and psychotherapy: keeping context and person in mind".

Assessment of attention in male and female Brattleboro rats using a self-paced five-choice serial reaction time task.

Intramuscular ziprasidone: influence of alcohol and benzodiazepines on vital signs in the emergency setting.

Developing Research Domain Criteria (RDoC) to improve diagnosis and treatment of social deficits in psychiatric disorders: the Mirror Neuron System as a model.

Oxytocin's role in anxiety: a critical appraisal.

Systemic administration of the neurotensin NTS₁-receptor agonist PD149163 improves performance on a memory task in naturally deficient male brown Norway rats.

Intranasal oxytocin administration prior to exposure therapy for arachnophobia impedes treatment response.

Efficacy and Safety of Low-field Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major Depression.

A Review of Oxytocin's Effects on the Positive, Negative, and Cognitive Domains of Schizophrenia.

Oxytocin modulates meta-mood as a function of age and sex.

Effects of intranasal oxytocin on neural processing within a socially relevant neural circuit.

Exposure to salient, dynamic sensory stimuli during development increases distractibility in adulthood.

Potential of Oxytocin in the Treatment of Schizophrenia.

Oxytocin's effect on resting-state functional connectivity varies by age and sex.